WET: Wells and Enteric Disease Transmission

Sponsor
Temple University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04826991
Collaborator
National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
908
1
2
44
20.6

Study Details

Study Description

Brief Summary

Approximately 40 million people in the US are served by private, and frequently untreated, wells. Our best estimate is that 1.3 million cases of gastrointestinal illnesses (GI) per year are attributed to consuming water from untreated private wells in the US, but in reality, there are no robust epidemiological data that can be used to estimate cases of GI attributable to these sources. We propose the first randomized controlled trial (RCT) to estimate the burden of GI associated with private well water. We will test if household treatment of private well water by ultraviolet light (UV) vs. sham (inactive UV device) decreases the incidence of GI in children under 5. We will also examine the presence of viral, bacterial, and protozoan pathogens in stool and well water from participants. These data will fill a knowledge gap on sporadic GI associated with federally-unregulated private water supplies in the US.

Condition or Disease Intervention/Treatment Phase
  • Device: Active UV Device
  • Device: Inactive UV Device
N/A

Detailed Description

Investigators will conduct a triple-blinded randomized controlled trial of a whole-home UV water treatment device in southeastern Pennsylvania. Participating families will be randomized to receive an active UV device or a sham (inactive) UV device. Following the installation of the device, participants will be followed for one year. During that year, participants will respond to weekly text messages to report the presence of symptoms associated with gastrointestinal and respiratory illness in their children. Upon reporting symptoms, participants will complete an illness questionnaire on details regarding the illness and other potential exposure events. A subset of participants will submit groundwater samples as well as stool and saliva samples from their children. Water and stool samples will be analyzed for common waterborne pathogens. Saliva samples will be analyzed for immunoconversions to common waterborne pathogens (exploratory aim).

Under the guidance of an interdisciplinary advisory committee we will execute the following aims:

Aim 1- Quantify the incidence rate of endemic childhood GI associated with consuming untreated private well water and compare that to the incidence rate of consuming well water treated by UV.

Aim 1a- Construct a Quantitative Microbial Risk Assessment (QMRA) using water quality data we collect to estimate the risk of childhood GI associated with consuming untreated private well water and compare the incidence from the risk model to the incidence we calculate in Aim 1.

Aim 2- Identify, quantify and compare viral, bacterial and protozoan pathogens in stool of children consuming UV treated or untreated (sham) private well water (including both asymptomatic and symptomatic cases).

Aim 3- Explore the presence of pathogens in untreated well water and stool samples of children consuming untreated private well water (sham group only).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
908 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
A whole-home UV water treatment system will be installed and operated at a minimum of 50 millijoules per square centimeter.A whole-home UV water treatment system will be installed and operated at a minimum of 50 millijoules per square centimeter.
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Masking Description:
Participants, device installers, investigators, and outcomes assessor will all be blinded.
Primary Purpose:
Prevention
Official Title:
Wells and Enteric Disease Transmission - A Randomized Trial of Children Supplied Drinking Water From Private Wells (WET-Trial)
Actual Study Start Date :
Jul 1, 2021
Anticipated Primary Completion Date :
Mar 1, 2025
Anticipated Study Completion Date :
Mar 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Active UV Device

A household water treatment device with a lamp emitting germicidal UV. The device will be operated at 50 millijoule per square centimeter to treat >99.9% of all bacteria, protozoa, and most viruses in water supplies.

Device: Active UV Device
Active water treatment system

Sham Comparator: Inactive UV Device

A household water treatment device with a lamp not emitting germicidal UV but still emitting light (appears identical to the active UV device).

Device: Inactive UV Device
Inactive water treatment system

Outcome Measures

Primary Outcome Measures

  1. Incident gastrointestinal illness [12 months]

    The investigators will collect data on the presence of gastrointestinal illness symptoms through weekly text messages. Households that report symptoms through text messages will be directed to an online illness questionnaire to characterize the symptoms (type, incidence, severity, duration, etc.), as well as relevant exposure information such as recent travel, exposure to ill persons, etc. Incident gastrointestinal illness (GI) is defined by the reporting of a minimum of three episodes of diarrhea or vomiting in a 24 hour period. Each illness will be considered distinct when separated by ≥ 6 symptom-free days.

Secondary Outcome Measures

  1. Acute respiratory infection [12 months]

    The investigators will collect data on the presence of acute respiratory infection symptoms through weekly text messages. Households that report symptoms through text messages will be directed to an online illness questionnaire to characterize the symptoms (type, incidence, severity, duration, etc.) as well as relevant exposure information such as recent travel, exposure to ill persons, etc. Acute respiratory infection is defined by the reporting of nasal congestion/discharge, sore throat or mouth sores, or cough lasting at least one day, in the absence of another explanation, such as isolated cough without nasal symptoms in known reactive airways disease. Each illness will be considered distinct when separated by ≥ 6 symptom-free days.

Eligibility Criteria

Criteria

Ages Eligible for Study:
6 Months to 59 Months
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Child resides in Berks, Bucks, Chester, Lancaster, Lehigh, or Montgomery County in Pennsylvania

  • Household is served by a private well

  • Participant child is under the age of 5 (under 4 at time of enrollment), who is a full-time resident of the home and drinks untreated well water

  • Parent/guardian has access to a phone with texting capabilities

Exclusion Criteria:
  • Child participant is immunocompromised

  • Child participant has a chronic gastrointestinal condition

  • Child takes daily oral steroids

  • Household treats water for microbiological contamination before consumption

  • Child exclusively drinks bottled water

Contacts and Locations

Locations

Site City State Country Postal Code
1 Temple University Philadelphia Pennsylvania United States 19122

Sponsors and Collaborators

  • Temple University
  • National Institute of Allergy and Infectious Diseases (NIAID)

Investigators

  • Principal Investigator: Heather M Murphy, PhD, Temple University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Heather Murphy, Adjunct Associate Research Professor, Temple University
ClinicalTrials.gov Identifier:
NCT04826991
Other Study ID Numbers:
  • 25665-A (Full Trial)
  • R01AI153376-01
First Posted:
Apr 1, 2021
Last Update Posted:
Aug 2, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Heather Murphy, Adjunct Associate Research Professor, Temple University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 2, 2022